Curaleaf Holdings (CURA) AI Stock Analysis

• Market Cap: C$2.85B
• Dividend Yield: N/A
• Average Volume (3M): 908.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: -3.38%
• EPS Growth: -31.35%
• Country: CA
• Employees: 5,519
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 672,456,200
• 10 Day Avg. Volume: 567,935
• 30 Day Avg. Volume: 908,378
• PEG Ratio: 0.57
• Price to Book (P/B): 1.34
• Price to Sales (P/S): 0.86
• P/FCF Ratio: 17.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$5.30
• Price Target Upside: 26.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: C$4.00 ▼(-4.76% Downside)

Curaleaf Holdings' overall stock score reflects significant financial challenges, including declining revenues and profitability issues, which are the most impactful factors. While technical analysis and valuation also present concerns, recent positive corporate events and a slightly positive earnings call sentiment provide some optimism. The company's strategic international expansion and improved cash flow are notable positives, but domestic market pressures and unprofitability weigh heavily on the score.

Positive Factors

International Growth

Strong international growth, particularly in the U.K. and Germany, indicates successful market expansion and diversification, which can provide a buffer against domestic challenges.

Improved Margins

Improved margins suggest better cost management and operational efficiency, enhancing profitability potential and financial resilience.

Strong Cash Flow

Strong cash generation supports liquidity and provides capital for strategic investments, crucial for sustaining growth and navigating market challenges.

Negative Factors

Price Compression Challenges

Price compression in the domestic market pressures margins and revenue, potentially limiting profitability and necessitating strategic adjustments.

Net Loss

The net loss reflects ongoing financial struggles, highlighting the need for improved cost control and revenue enhancement strategies to achieve profitability.

Domestic Revenue Decline

Declining domestic revenue suggests market saturation or competitive pressures, necessitating innovation and market repositioning to regain growth.

Curaleaf Holdings Business Overview & Revenue Model

Company Description

Curaleaf Holdings, Inc. is a leading vertically integrated cannabis operator in the United States, specializing in the production, distribution, and sale of cannabis products. The company operates in multiple sectors of the cannabis industry, including cultivation, manufacturing, and retail. Curaleaf offers a diverse range of products, including cannabis flower, edibles, oils, and topicals, catering to both medical and adult-use markets across various states.

How the Company Makes Money

Curaleaf generates revenue primarily through the sale of its cannabis products across its dispensary network and wholesale distribution to third-party retailers. The company's revenue model is supported by its extensive cultivation facilities, which allow for in-house production of a wide array of products, enhancing profit margins. Key revenue streams include retail sales from its dispensaries, where customers can purchase both medical and recreational cannabis, and wholesale sales to other dispensaries and retailers. Additionally, Curaleaf benefits from strategic partnerships and collaborations that enhance its market presence and distribution capabilities. The company's operations in states with established cannabis markets and its focus on expanding its footprint into new markets further contribute to its earnings potential.

Curaleaf Holdings Financial Statement Overview

Summary

Curaleaf Holdings faces significant financial challenges, with declining revenues, negative profitability, and cash flow constraints. While the balance sheet shows moderate leverage, the company's inability to generate positive returns and cash flow is a major concern for its financial health.

Income Statement

Curaleaf Holdings has experienced declining revenue growth with a negative trend in net profit margins, indicating challenges in maintaining profitability. The gross profit margin remains moderate, but EBIT and EBITDA margins have shown volatility, reflecting operational inefficiencies.

Balance Sheet

The company has a balanced debt-to-equity ratio close to 1, suggesting moderate leverage. However, the negative return on equity indicates that the company is not generating sufficient returns on shareholders' equity, which is a concern for investors.

Cash Flow

Curaleaf's cash flow situation is concerning, with negative free cash flow growth and low operating cash flow coverage ratios. The free cash flow to net income ratio indicates that the company struggles to convert earnings into free cash flow, highlighting liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.34B	1.35B	1.34B	1.21B	626.64M
Gross Profit	625.61M	639.25M	614.45M	579.03M	687.59M	390.51M
EBITDA	220.14M	233.14M	238.76M	220.97M	278.98M	128.59M
Net Income	-244.34M	-215.42M	-281.20M	-376.93M	-109.13M	-61.33M
Balance Sheet
Total Assets	2.92B	2.95B	3.10B	3.41B	3.11B	2.39B
Cash, Cash Equivalents and Short-Term Investments	102.27M	93.03M	91.82M	163.18M	299.33M	73.54M
Total Debt	843.02M	853.82M	883.55M	931.91M	652.40M	577.71M
Total Liabilities	1.98B	1.96B	1.93B	2.01B	1.44B	1.01B
Stockholders Equity	871.30M	861.21M	1.05B	1.28B	1.55B	1.38B
Cash Flow
Free Cash Flow	49.54M	64.42M	5.05M	-91.96M	-205.92M	-113.92M
Operating Cash Flow	136.37M	162.57M	75.26M	46.40M	-33.96M	12.36M
Investing Cash Flow	-87.48M	-93.83M	-78.69M	-228.62M	-163.97M	-197.11M
Financing Cash Flow	-37.76M	-54.24M	-67.02M	50.54M	424.80M	224.08M

Curaleaf Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Positive. The current price of 4.2 is above the 20-day moving average (MA) of 3.25, above the 50-day MA of 3.76, and above the 200-day MA of 2.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.34 is Neutral, neither overbought nor oversold. The STOCH value of 70.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CURA.

Curaleaf Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	67 Neutral	C$1.32B	28.22	3.34%	―	22.20%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CURA	51 Neutral	C$2.85B	―	-27.61%	―	-3.38%	-31.35%
ACB	49 Neutral	C$352.13M	―	-10.76%	―	23.87%	-19.57%
CL	49 Neutral	C$467.17M	―	-11.79%	―	-6.48%	22.63%
TRUL	46 Neutral	C$1.53B	―	-9.95%	―	4.27%	3.41%
WEED	43 Neutral	C$589.53M	―	-60.19%	―	-0.67%	58.98%

Curaleaf Holdings Corporate Events

Curaleaf Expands with Acquisition of Virginia Assets from The Cannabist Company

Curaleaf Holdings has entered into a binding agreement to acquire The Cannabist Company’s Virginia assets, including a cultivation facility and multiple dispensaries. This acquisition, expected to close in early 2026, aims to strengthen Curaleaf’s market position in Virginia, subject to a go-shop period and potential competing bids.

Curaleaf Holdings Reports Q3 2025 Results: Revenue Growth and Strategic Expansion

Curaleaf Holdings reported a net revenue of $320 million for the third quarter of 2025, marking a 2% sequential increase despite a 3% year-over-year decline. The company’s international segment showed robust growth, with a 12% sequential and 56% year-over-year increase in revenue. The adjusted gross profit margin improved to 50%, and the company generated significant operating and free cash flow, ending the quarter with $107 million in cash. Curaleaf’s strategic initiatives, including the ‘Return to Our Roots’ plan, have positioned it for renewed domestic growth and rapid international expansion, despite ongoing macroeconomic challenges.

Curaleaf Secures Landmark $100 Million Credit Facility in Cannabis Sector

Curaleaf Holdings, Inc. has expanded its revolving credit facility with Needham Bank from $40 million to $100 million, marking the largest facility of its kind in the U.S. cannabis sector. This move reflects increased confidence from institutional lenders and is expected to enhance Curaleaf’s financial flexibility, support its strategic growth initiatives, and contribute to the broader acceptance of cannabis businesses in capital markets.

Curaleaf Announces Executive Securities Disposition Plan

Curaleaf Holdings announced the establishment of an automatic securities disposition plan (ASDP) by its Executive Vice Chairman, Joseph F. Lusardi, to facilitate the orderly exercise of options expiring in March 2026 and the sale of some subordinate voting shares to cover taxes. This plan, compliant with U.S. and Canadian securities laws, allows insiders to sell shares according to pre-arranged instructions, ensuring transparency and compliance. The ASDP will be executed by an independent broker, with sales commencing in January 2026, potentially impacting the company’s stock liquidity and insider trading transparency.

Curaleaf to Announce Q3 2025 Financial Results

Curaleaf Holdings announced it will release its third-quarter 2025 financial and operational results on November 5, 2025, after market close. The announcement will be followed by a conference call and audio webcast, providing insights into the company’s operational and financial highlights. This release is significant for stakeholders as it offers an opportunity to gauge Curaleaf’s performance and strategic direction in the evolving cannabis market.

Curaleaf Joins S&P/TSX Composite Index, Boosting Market Visibility

Curaleaf Holdings, Inc. has been included in the S&P/TSX Composite Index under the Health Care sector, marking a significant milestone as the first U.S.-based cannabis operator to join this prestigious index. This inclusion enhances Curaleaf’s visibility and credibility in North American capital markets, potentially increasing its access to institutional investments and index-linked vehicles, thereby supporting its growth and development in the evolving cannabis industry.